Small RNAs may Play Big Role in Embryonic Stem Cells
News Apr 12, 2008
An international team led by scientists at The Scripps Research Institute has used a new method to discover an unusual molecular signature in human embryonic stem cells that may lead to development of new cell-based therapeutics.
The team reports that human embryonic stem cells, which are pluripotent and self-renewing, contain a unique group of small molecules, called microRNAs, that are known to control production of proteins in cells.
By examining 14 different strains of human embryonic stem cells, and comparing them to a large group of other cell types, the scientists discovered that the embryonic stem cells all shared the same profile of microRNAs.
The study was published April 10, 2008, in an advance, online edition of the journal Stem Cells.
"This is a landmark study," said Jeanne Loring, a professor at Scripps Research and director of the Scripps Research Center for Regenerative Medicine, who led the study with Louise Laurent, a clinical fellow in her lab, and Jian-Bing Fan from Illumina, Inc. "We report the most comprehensive determination of microRNA expression in human embryonic stem cells to date and detail differences in microRNA expression that may be key to regulating stem cell pluripotence—the ability to change into other cell types."
This study also documents the first report of a new method for analyzing microRNAs—a microarray that enables scientists to rapidly conduct genetic testing on a mass scale. The microarray allowed the researchers to measure more than 700 different microRNAs in 26 different cell types.
First discovered in the roundworm C. elegans, microRNAs are small, naturally occurring bits of RNA, a part of the human genome known to control critical points in the development of plants and lower animals. However, the exact role of microRNAs in mammalian development is still not well understood.
Although microRNAs do not code for protein expression by the cell, they do control the activity of genes through their influence on messenger RNA. Once thought of as mere genetic helpers, it has now been shown that microRNAs can prevent proteins from being produced by messenger RNA.
"MicroRNAS are high-level regulators," Loring said. "They control whole suites of proteins and signaling processes. Our most important discovery is that microRNAs made specifically by human embryonic stem cells almost all share the same 'seed sequence.' (Seed sequences are the parts of microRNAs that interact with cellular machinery and regulate synthesis of proteins.) We're certain that the shared seed sequences aren't an accident. Embryonic stem cells are actively and robustly preventing the synthesis of certain proteins, and this may be key to maintaining their unique qualities of self-renewal and pluripotence."
In the new study, the researchers found that that a significant proportion of microRNAs in human embryonic stem cells occur in clusters in the genome, including two very large clusters not previously associated with stem cells. Because of its location in the genome, the study said, one of the clusters could play a role in chromosomal abnormalities that often lead to the development of cancer.
The study also found that oncogenic microRNAs, which are associated with human cancers, are overrepresented in human embryonic stem cells, while tumor suppressor microRNAs are unusually rare. This suggests that while human embryonic stem cells are not closely related to any one type of cancer cell, they may share some self-renewal mechanisms with cancer cells as a class, the study said.
"The point is," Loring said, "that while oncogenic microRNAs are highly expressed in some human embryonic stem cells, the cells themselves are not oncogenic. This might be a cautionary tale, though, with the moral that we pay particular attention to changes made in cellular microRNA so we don't trigger any abnormal events."
But the most important aspect of their work, Loring believes, is that some day in the future microRNAs may be used to reprogram any cell type to become as pluripotent as embryonic stem cells. "It should be possible to treat cells with a mixture of microRNAs," she said, "to reprogram them to become blood cells or cardiac cells or neurons."
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018